Pomalidomide is sold under the brand name Pomalid 1mg and it belongs to anti neoplastics drugs, Pomalid 1mg is doable as orally bioavailable thalidomide derivative asssociated with numerous therapeutic activities @MHP
Pomalidomide is sold under the brand name Pomalid 1mg and it belongs to anti neoplastics drugs
Pomalid 1mg is doable as orally bioavailable thalidomide derivative asssociated with numerous therapeutic activities such as: immune modulatory, anti-angiogenesis, anti neoplastic. Pomalid 1mgcombination with dexamethasone will cause liver injury
The primary indication of Pomalid 1mg Tablet is used in the treatment of Multiple Myeloma condition. In this condition, Pomalid 1mg Tablet is used by combining with dexamethasone. Pomalid 1mg capsules are applicable in; Previously the Patients treated with two treatment such as proteasome inhibitor & Lenalidomide. Patients who are suffered with disease progression condition Pomalid 1mg treatment should be followed within 60 days in patients who are concluded the last treatment.
POMALID 1MG WORKS AS
Pomalid has three primary pharmacological activities against cancer cells. Pomalidomide includes in the way cancer proliferation and provoke the apoptosis of cancer cells. Pomalidomide enhance the T cell & natural killer cells interceding immunity & inhibits the formation of pro inflammatory cytokines from monocytes. Pomalidomide forbid the new cell formation. The binding of Pomalidomide to active site of targeted cell causes inhibition of ubiquitin ligase action.
ADME PROPERTIES
The time to high serum concentration of Pomalidomide is reaches between 2 to 3 hours. It should be administered with or without food. Hence No effect of food should be produced; Volume of distribution of Pomalidomide is between 62 & 138L in steady state.
The Pomalidomide distribution by 67% of serum level at after 4 hours of drug intake. human plasma protein by bounding range of 12% & 44%. Hepatically mediated through CYP1A2, CYP3A4 is Pomalidomide is metabolized.
Pomalidomide clearance value is 7 to 10L/hr. Doses are excreted via urine 73% & feces 15% respectively. Doses are excreted as an unchanged form via urine 2% & feces 8%. Pomalidomide half life period is 9.5 hours.
Brand : Pomalid
Ingredients : Pomalidomide
Strength : 1mg
Manufactured : Natco
Package : 21 Tablets
DURING MULTIPLE MYELOMA MALIGNANCIES
The dosage recommendation of Pomalid 1mg is 4mg should be administered as a single dose for 1 to 21 days of successive 28 day cycles. Pomalid is combined with dexamethasone with low dose. Administrate Dexamethasone on day 1, 8, 15 & 22 of each 28 day cycle. The prescribed dose of dexamethasone is 40mg should be administered the patient having weight about ≤ 75kg. The prescribed dose of dexamethasone is 20mg given for patient’s weight Greater than 75kg
DOSAGE ALTERATION DURING HEMATOLOGICAL TOXICITIES NEUTROPENIA
ANC <500/mcL: Pomalid treatment should be postponed and check the CBC weekly. ANC ≥ 500/mcL: Pomalid therapy should be continued by 3mg/day For each successive drop <500/mcL: Pomalid 1mg should be postponed. ANC ≥ 500/mcL: Continue the Pomalid therapy with 1mg/day.
THROMBOCYTOPENIA
Platelets count <25000/mcL: Pomalid therapy should be postponed and check CBC Platelets count ≥50000/mcL: 3mg of Pomalid should be taken daily
WITH STRONG CYP1A2
Pomalid combined with CYP1A2 substrates causes increasing the plasma concentration of Pomalidomide and leads to elevate the risk of Pomalidomide.
IN RENAL DAMAGED PATIENTS
In severe renal impaired patients, the suggested dose of Pomalid is 3mg per day.
IN HEPATIC IMPAIRED PATIENTS
The advised dose is 3mg/day & in severe condition, the suggested dose is 2mg/day given for mild to moderate patients.
CONTACT US
MOBILE NO : +91-9940472902
EMAIL : millionhealthpharmaceuticals@gmail.com
WEBSITE URL : https://millionpharma.com/pomalid-1mg.php